UBS Maintains Buy on Encompass Health, Raises Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Andrew Mok maintains a Buy rating on Encompass Health (NYSE:EHC) and raises the price target from $96 to $100.
August 08, 2024 | 1:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Andrew Mok maintains a Buy rating on Encompass Health and raises the price target from $96 to $100.
The Buy rating and increased price target from a reputable analyst at UBS is likely to positively impact investor sentiment and drive short-term price appreciation for Encompass Health.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100